We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Hologic to Buy Gen-Probe for USD 3.72 Billion

By LabMedica International staff writers
Posted on 11 Feb 2013
Hologic (Bedford, MA, USA) announced that it will buy Gen-Probe (San Diego, CA, USA) in an all-cash deal valued at USD 3.72 billion. More...
The purchase will allow Hologic to expand its growing diagnostics products and services business. The transaction is expected to close in the second half of the year (2013) and should result in USD 75 million in cost savings in its first three years, the companies said.

Hologic has been steadily building its diagnostics business, domestically and abroad. Last year, it acquired TCT International, a Chinese distributor of medical products, for USD 135 million in cash. The diagnostics business is one of the company’s fastest growing segments, according to Hologic’s second-quarter earnings report. For the six months ended March 24, the unit’s sales rose 10.3% from the period a year earlier. Hologic attributed the gain to growth in ThinPrep, its Pap test product. Hologic, Inc. is a leading developer, manufacturer, and supplier of premium diagnostic products, medical imaging systems, and surgical products. The company operates four core business units focused on diagnostics, breast health, GYN surgical and skeletal health.

Gen-Probe is a maker of molecular diagnostics products that are used to screen for blood diseases and test transplant compatibility, among other things. The combined businesses expect to generate annual revenue of about USD 2.4 billion.

“Gen-Probe is an ideal partner and strategic fit to Hologic’s existing diagnostics business and complements our focus on scaling and diversifying our diagnostics franchise,” Robert A. Cascella, the chief executive of Hologic, said in a statement. “Our combined company will be well positioned globally to capitalize on the fast-growing molecular diagnostics market with an established global infrastructure.”

Related Links:

Hologic
Gen-Probe



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.